A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients with Moderately to Severely Active Ulcerative Colitis” LUCENT 2

drug protocol number
I6T-MC-AMBG
drug sponsor
Eli Lilly
drug study
Mirikizumab
drug trial site
KFSH-D
drug status
Ongoing
drug phase